Clinical trials of a drug to reduce harm from chemotherapy have begun in Russia
Russia has started trials of a drug to reduce the harm caused by chemotherapy. The drug has a polysaccharide nature and a mechanism of action different from foreign analogs.Siberian State Medical University (SibGMU) has received permission from the Russian Ministry of Health for clinical trials of a drug that reduces harmful effects of chemotherapy, Interfax reported with reference to the press service of the university. The development of the drug, designed to replace imported analogs, has been underway at SibGMU since 2003.
The university noted that in foreign practice genetically engineered biological drugs - recombinant proteins - are used to reduce the consequences of chemotherapy, they are expensive, are administered only by drip and cause frequent allergic reactions. The development of SibGMU has a polysaccharide nature and a different mechanism of action, the drug is no less active, but causes fewer allergic reactions and will cost much cheaper.
Preclinical trials have shown that in combination with chemotherapy, the drug can reduce the number of metastases by 90%.
Preclinical trials have shown that in combination with chemotherapy, the drug is able to reduce the number of metastases by 90%.